Showing 4291-4300 of 9330 results for "".
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2458016/The American Society for Dermatologic Surgery (ASDS) introduced their new Vice President and three members of the Board of Directors the 2017 ASDS Annual Meeting in Chicago. Their terms officially began on Oct. 6 Lisa M. Donofrio, MD, succeeds ASDS President Thomas E. Rohrer, MD, who becomes the S…
- ASDS Cutting Edge Research Grants Awardedhttps://practicaldermatology.com/news/asds-cutting-edge-research-grants-awarded/2458019/The American Society for Dermatologic Surgery (ASDS) awarded a total of $96,669 to eight new research projects as part of rhe Cutting Edge Research Grant program The program was introduced in 1999 with the goal of uniting education and innovation to encourage clinical research and the transfer of …
- Lisa M. Donofrio, MD Takes Reins of ASDS/ASDSAhttps://practicaldermatology.com/news/lisa-m-donofrio-md-takes-reins-of-asdsasdsa/2458023/Lisa M. Donofrio, MD, is the new President of the American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA). Along with her fellow officers and the ASDS / ASDSA Boards of Directors, Dr. Donofrio assumed leadership of theASDS/ASDSA at the 201…
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial treatment areas…
- Happy 70th Cetaphil!https://practicaldermatology.com/news/happy-70th-cetaphil/2458051/Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partners nationwide running from September 17, 2017 at 12:00am EST through September 19, 2017 at 10pm EST. (Con…
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report," appears in the British Journal of Dermatology and is ba…
- FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Usehttps://practicaldermatology.com/news/fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use/2458057/The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact dermatitis (ACD). ACD may affect as many as 20% of the pediatric popula…
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA set a target acti…
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea (MOSAIC) study shows. “Concomitant administr…
- Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agenthttps://practicaldermatology.com/news/link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent/2458065/Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful conditions in the tumor micro…